Related references
Note: Only part of the references are listed.MenACWY-TT vaccine for active immunization against invasive meningococcal disease
Vassiliki Papaevangelou et al.
EXPERT REVIEW OF VACCINES (2012)
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
Ghassan Dbaibo et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2012)
A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers
Jodie McVernon et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11-17 years: An open, randomised, controlled trial
Lars Ostergaard et al.
VACCINE (2012)
Increase of meningococcal serogroup Y cases in Europe A reason for concern?
Michael Broeker et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
An evaluation of emerging vaccines for childhood meningococcal disease
Debajeet Choudhuri et al.
BMC PUBLIC HEALTH (2011)
Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century
Paula Kriz et al.
EXPERT REVIEW OF VACCINES (2011)
Cost impact of complications in meningococcal disease Evidence from a United States managed care population
Keith L. Davis et al.
HUMAN VACCINES (2011)
Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
Nancy Bermal et al.
HUMAN VACCINES (2011)
Bacterial Meningitis in the United States, 1998-2007
Michael C. Thigpen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2-to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile
Ziad A. Memish et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
Roger Baxter et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children
Markus Knuf et al.
VACCINE (2011)
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial
Timo Vesikari et al.
VACCINE (2011)
Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo (R)) In Adolescents and Adults
Emma D. Deeks
BIODRUGS (2010)
Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
Helen Campbell et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Epidemiological Profile of Meningococcal Disease in the United States
Lee H. Harrison
CLINICAL INFECTIOUS DISEASES (2010)
Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease
Amanda C. Cohn et al.
CLINICAL INFECTIOUS DISEASES (2010)
Optimizing Protection Against Meningococcal Disease
Keith S. Reisinger et al.
CLINICAL PEDIATRICS (2010)
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
Christopher J. Gill et al.
HUMAN VACCINES (2010)
CURRENT CONCEPTS Advances in the Development of Vaccines against Neisseria meningitidis
Lionel K. K. Tan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
M. Knuf et al.
VACCINE (2010)
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
Caroline L. Trotter et al.
EXPERT REVIEW OF VACCINES (2009)
Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution
F. Marc LaForce et al.
VACCINE (2009)
Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages
Michael Broeker et al.
VACCINE (2009)
Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years
Lars Ostergaard et al.
VACCINE (2009)
Global epidemiology of meningococcal disease
Lee H. Harrison et al.
VACCINE (2009)
Meningitis epidemics in africa: A brief overview
Remy Teyssou et al.
VACCINE (2007)
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
David S. Stephens et al.
LANCET (2007)
Meningococcal meningitis:: Unprecedented incidence of serogroup X-related cases in 2006 in Niger
Pascal Boisier et al.
CLINICAL INFECTIOUS DISEASES (2007)
Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines
Caroline L. Trotter et al.
FEMS MICROBIOLOGY REVIEWS (2007)
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
Cressida Auckland et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals
Jozef J. P. Nauta et al.
VACCINE (2006)
A review of vaccine research and development: Meningococcal disease
Marc P. Girard et al.
VACCINE (2006)
Prospects for vaccine prevention of meningococcal infection
LH Harrison
CLINICAL MICROBIOLOGY REVIEWS (2006)
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
CL Trotter et al.
LANCET (2004)
Medical progress: Meningococcal disease.
NE Rosenstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection
R Borrow et al.
INFECTION AND IMMUNITY (2001)
Share Paper
